The Sixth Annual Innovators in Urology meeting took place this year in Vancouver, Canada under the chairmanship of Professor Martin Gleave from Vancouver, Canada. A total of 32 delegates from 17 countries were invited to attend the meeting and disciplines included urology, radiotherapy and medical oncology. The following is a summary of key abstracts from the meeting.
Polymorphisms of the 5a-reductase type 2 and the androgen receptor genes in men with prostate cancer Dr Goran Ahlgren (Malmö , Sweden) presented findings on polymorphisms in the androgen receptor (AR) and the 5a-reductase type 2 (SRD5A2) genes. Studied were the CAG and GGN polymorphisms in the AR-gene and the A49T, V89L and R227Q polymorphisms in the SRD5A2 gene in cohorts of men with prostate cancer (n ¼ 89), BPH (n ¼ 45) and young healthy men (n ¼ 223). Results showed that the heterozygous AT variant in SRD5A2 was significantly more common in men with prostate cancer compared with healthy controls (P ¼ 0.026) but not in men with BPH. There were no differences in the GAG or GGN polymorphisms between men with prostate cancer, BPH and controls. Death from prostate cancer was more common in men with GGNo23, which was true also in a multivariate analysis (P ¼ 0.03) with pretreatment PSA (P ¼ 0.06), M-stage (Po0.0001) and age at diagnosis (P ¼ 0.008). Notably, regarding the SRD5A2 gene, one case of death due to prostate cancer occurred among men with the AT genotype, whereas 16 cases were found in the AA group. However, these findings need to be confirmed in a larger patient group. Previously, the AT variant has been shown to have a higher enzymatic activity in vitro than the homozygous AA variant. The GGN-polymorphism in the AR-gene might be important for the outcome of prostate cancer, although the functional role of the GGN-repeat in the AR is unknown.
IGF-1 levels and PIN
Serum insulin-like growth factor-1 (IGF-1) levels at the higher end of the normal range have been associated with increased risk of future development of prostate cancer. Dr Robert Nam (Toronto, Canada) presented data from a case-control study that determined whether high serum IGF-1 levels were associated with the presence of high-grade prostatic intraepithelial neoplasia (HGPIN). Serum IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) prior to prostate biopsy were measured in 103 men with HGPIN (cases) and 205 men with normal prostate histology (controls). Results showed that mean IGF-1 level in patients with HGPIN (130.2 ng/ml) was significantly higher compared with controls (118.8 ng/ml; P ¼ 0.01). The mean IGFBP-3 level in patients with HGPIN (2393.9 ng/ml) was also higher compared with controls (2276.0 ng/ml; P ¼ 0.06). After adjusting for age, prostate-specific antigen (PSA), digital rectal examination and ethnic background, the odds ratio for an HGPIN diagnosis among men in the highest relative to the lowest quartile of serum IGF-1 level was 1.94 (95% C.I.: 1.0-3.7; P ¼ 0.04). It was concluded that the potential association between a high serum IGF-1 level and the presence of HGPIN may help the understanding of the relationship between IGF-1 physiology and prostate cancer risk.
Effect of timing of castration and chemotherapy on time to androgen-independent progression in Shionogi tumour model Dr Alan So (Vancouver, Canada) and co-workers used the androgen-dependent Shionogi tumour model to help define the effects of timing of androgen ablation on development of androgen independence (AI) and the optimal timing and sequencing of chemotherapy when combined with androgen ablation (AA). While AA is the most effective therapy for advanced prostate cancer, the optimal timing of androgen ablation remains controversial, especially in the PSA era, with an increased proportion of PSA-relapses after failed local therapy. Also, recent trials identify a survival advantage for docetaxel in the management of hormone-refractory prostate cancer (HRPC), generating future questions on optimal timing and sequencing of chemohormonal regimens in hormone-naïve disease. Groups of nine mice were castrated on days 1, 3, 6, 10, and 14 post-tumour inoculation and a similar sized group of mice castrated on day À1 served as a control. Time of first palpable tumour recurrence and tumour volume was monitored post-castration. To assess ideal timing and sequencing of AA with paclitaxel, three groups of 10 mice were treated with: (1) initial castration and delayed paclitaxel, (2) initial paclitaxel and delayed AA, or (3) initial combined therapy. The investigators found that mice castrated at 14 days had the highest rate of early tumour recurrence 100% (9/9) while mice castrated before inoculation or at days 1 and 3 postinoculation had a significantly lower rate of tumour recurrence (44% or 4/9; Po0.01). Mice castrated at days 14 and 10 were the only groups to have palpable tumours prior to castration and developed tumour recurrence rates significantly earlier than other groups. Also, mice treated initially with combined chemotherapy and AA had the best tumour response and overall time to AI progression when compared to sequential therapy, either initiated with chemotherapy or hormonal therapy. Interestingly, a marked lack of response to castration in the mice treated with paclitaxel first was observed. Gene expression and RT-PCR studies confirmed that several genes known to play a role in androgen independence, including clusterin, bcl-2, and Hsp27, became upregulated in response to paclitaxel exposure. These experiments suggest that earlier androgen ablation, at time of subclinical (nonpalpable) disease, significantly delayed the rate and time to AI recurrence compared to delayed therapy when tumour burden was high. With palpable disease, optimal tumour response and delayed time to progression occurred with combination chemohormonal, rather than sequential, therapy.
PCA3 gene-based analysis of urinary sediments as prognostic value
It has previously been shown that the PCA3 gene is strongly overexpressed in prostate cancer epithelial cells due to a unique mechanism of transcriptional regulation. Dr Peter Mulders (The Netherlands) and co-workers have demonstrated that cancer cells can be detected in urinary sediments after extended digital rectal examination. A study has been conducted to determine whether PCA3 might have a potential diagnostic application by examining the ratio PCA3/PSA mRNA in prostate cells in urinary sediments. In addition, the hypothesis that aggressive cells are more invasive and thus are more likely to mobilize and shed into the ductal system was examined. The histopathology of biopsy specimens in 94 patients was compared with the PCA3/PSA mRNA ratio obtained immediately before the biopsies. A clear correlation was observed between Gleason score and the level of PCA3/PSA mRNA ratios. The mean value in Gleason IV and V was 0.05 and 600 in Gleason 6 and 7 grades.
A phase I study of OGX-011, a 2 0 methoxyethyl phosphorothioate antisense to clusterin
The clusterin gene encodes a cytoprotective chaperone protein that promotes cell survival. Clusterin is expressed in a variety of cancers, including prostate, increases in response to apoptotic stimuli and in preclinical models confers a resistant phenotype. Dr Kim Chi (Vancouver, Canada) and associates have conducted a pharmacokinetic and pharmacodynamic study of OGX-011 (Oncogenex Technologies Inc.), a second-generation antisense complimentary to clusterin mRNA. A total of 25 patients with localized prostate cancer with high-risk features and candidates for prostatectomy were enrolled in the study. OGX-011 was given by IV infusion over 2 h at a starting dose of 40 mg on days 1, 3, 5, 8, 15, 22, and 29 . Buserelin and flutamide were started on day 1.
Prostatectomy was performed on days 30-36. OGX-011 plasma PK and prostate tissue concentrations were determined. Prostate tissues, lymph nodes, and serial samples of peripheral blood mononuclear cells and serum were assessed for clusterin expression. Results showed that OGX-011 was well tolerated and could inhibit clusterin expression in primary prostate cancers. The recommended phase II dose for OGX-011 is 640 mg based on pharmacokinetic parameters and target regulation results.
Androgen suppression with or without radiation therapy in clinically localized prostate cancer Two reports have been made on androgen suppression as neoadjuvant to radiotherapy. D'Amico AV et al (JAMA 2004; 292: 821-827) report that the addition of 6 months of androgen suppression therapy to 70 Gy three-dimensional conformal radiation therapy (3D-CRT) confers an overall survival benefit for patients with clinically localized prostate cancer. This prospective controlled trial of 206 patients randomized treatment to 70 Gy 3D-CRT alone (n ¼ 104) or in combination with 6 months of androgen suppression therapy (n ¼ 102). Patients included in the study had minimum PSA level of 10 ng/ ml, a Gleason score X7, or radiographic evidence of extraprostatic disease. After a median follow-up of 4.52 y, patients randomized to receive 3D-CRT plus androgen suppression therapy had a significantly higher survival (P ¼ 0.04), lower prostate cancer-specific mortality (P ¼ 0.02), and higher survival free of salvage androgen suppression therapy (P ¼ 0.002). Kaplan-Meier estimates of 5-y survival rates were 88% (95% confidence interval (CI), 80-95%) in the 3D-CRT plus androgen suppression therapy group vs 78% (95% CI, 68-88%) in the 3D-CRT group.
Crook J et al (Int J Radiat Oncol Biol Phys 2004; 60: 15-23) randomized 378 men to either 3 or 8 months of flutamide and goserelin before conventional-dose RT (66 Gy). The median baseline PSA level was 9.7 ng/ml (range: 1.3-189 ng/ml). Of the 378 men, 26% were low risk (Stage T1c-T2a, GSp6, PSA o10 ng/ml), 43% were intermediate risk (Stage T2b or GS 7 or PSA 10-20 ng/ml) and 31% were high risk (Stage T3 or GS 8-10 or PSA420 ng/ml). The 8-month arm achieved a lower PSA level before starting radiotherapy (0.37 vs 0.74 ng/ml; Pp0.001) and had a greater downsizing of the prostate (mean volume 26.6 ml vs 30.5 ml; Pp0.001). However, the actuarial freedom from failure rate (biochemical by American Society for Therapeutic Radiology and Oncology definition, local or distant) for the 3-month vs 8-month arms at 3 y was 66 vs 68% and by 5 y was 61 vs 62%, respectively
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M Gleave and CP Evans (P ¼ 0.36). A suggestion of improvement was found in the 8-month arm for disease-free survival at 5 y for highrisk patients (39 vs 52%) but did not achieve statistical significance. These findings suggest that a longer period of neoadjuvant hormonal therapy before standard-dose radiotherapy does not appear to confer a benefit in terms of disease-free survival or to alter failure patterns.
Effect of a dual 5a-reductase inhibitor on markers of prostate tumour regression
It has been suggested that suppression of dihydrotestosterone (DHT) formation by 5a reductase inhibition may be beneficial in early treatment or prevention of prostate cancer. Andriole et al (J Urol 2004; 172: 915-919) have published findings from a study that examined the roles of the dual 5a-reductase inhibitor dutasteride in prostate cancer prevention. A total of 46 men with clinically staged T1 or T2 prostate cancer were randomized to receive placebo or dutasteride 5 mg/day for 6-10 weeks before radical prostatectomy. Resected tissues were analyzed to determine the effect of dutasteride on intraprostatic androgen levels, and indices of apoptosis and microvessel density (MVD) in malignant tissue, as well as degree of atrophy in benign tissue. It was shown that dutasteride treatment caused a 97% decrease in intraprostatic DHT and was associated with a trend toward increased apoptosis. In patients receiving dutasteride for 45 days or more, a significant increase in apoptosis and a trend toward decreased MVD in prostate cancer tissue was observed. Dutasteride treatment was also associated with an 18% decrease in mean benign epithelial cell width compared with placebo (Po0.0001). It was concluded that dutasteride treatment resulted in almost complete suppression of intraprostatic DHT, increased apoptosis and a trend toward decreased MVD. These findings suggest that short-term treatment with dutasteride can cause regression in some prostate cancers.
Chemoprevention of prostate cancer:
The REDUCE trial
The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Study group (J Urol 2004; 172: 1314 -1317 have published details of the REDUCE clinical trial, an international, multicentre, double-blind, placebocontrolled chemoprevention study designed to determine if dutasteride 0.5 mg daily decreases the risk of biopsy detectable prostate cancer. A total of 8000 men will be randomized to receive dutasteride or placebo for 4 y. Men aged 50-75 y old, with a serum PSA of 2.5-10 ng/ml (ages 50-60 y) or 3.0-10 ng/ml (460 y) will be enrolled in the study. Men must have a negative 6-12 core biopsy within 6 months prior to enrolment; repeat biopsies will be taken at 2 and 4 y. The rates of prostate cancer for each treatment group will be compared. Genetic and protein biomarkers of prostate cancer and the effect of dutasteride on BPH and prostatitis symptomatology and histopathology will also be assessed. Bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain report on the use of the surface bone-seeking radiopharmaceuticals rhenium-188-HEDP and samarium-153-EDTMP in pain palliation for bone metastases in prostate (n ¼ 34) and breast cancer (n ¼ 12) patients. All patients had an interview using standardized sets of questions before and after therapy. After 12 weeks of therapy with rhenium-188-HEDP, 77% of patients reported pain relief and 73% after samarium-153-EDTMP. Of the patients treated with rhenium-188-HEDP or samarium-153-EDTMP, 16 and 13%, respectively could discontinue their analgesics and were pain free. Statistically significant improvements in the Karnofsky performance scale were reported after 12 weeks of therapy with rhenium-188-HEDP (Po0.05). Thrombocytopenia was reported in three patients on rhenium-188-HEDP therapy and two on samarium-153-EDTMP. The maximum nadir of platelet and leukocyte counts were observed between the second and fourth week after treatment in both and was reversible within 12 weeks. It was concluded that both radiopharmaceuticals were effective in pain palliation, without induction of severe side effects or significant differences in therapeutic efficacy or toxicity.
LUTS and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)
Rosen R et al (Prog Urol 2004; 14: 332-344) report on a study that investigated the relationship between lower urinary tract symptoms (LUTS) and sexual problems in aging men. This large-scale, multinational survey was conducted in the US and six European countries to systematically investigate the relationship between LUTS and sexual dysfunction in older men. Detailed questionnaires were mailed to a national representative sample of men aged 50-80 y in each country. Selection was made on the basis of age, occupation, geographic region and population density. LUTS and sexual function Results were robust across a wide range of sensitivity analyses. The authors of the report conclude that combination therapy with finasteride and doxazosin is cost-effective compared with doxazosin alone with cost-utility ratios under $40,000/QALY across a wide range of scenarios.
TUNA vs TURP: 5-year follow-up
The 5-y efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared with transurethral resection of the prostate (TURP) for the treatment of LUTS secondary to BPH has been reported by Hill and associates (J Urol 2004; 171(6, Part 1): 2336-2340). A total of 121 men 50 y or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at seven medical centres in the US.
Statistically significant Improvements from baseline for both treatment groups were reported for IPSS, quality of life and peak flow rate at each year of follow-up. Postvoid residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. With regard to adverse events, there was a 41% incidence of retrograde ejaculation in the TURP group compared with 0% in the TUNA group. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. In placebo treated patients, the mean effect on peak urinary flow rate was an increase of 1.20 (0.49) ml/s. The estimated effect of permixon was a further increase of 1.02 (0.50) ml/s (P ¼ 0.042). Placebo was associated with a reduction in the mean number of nocturnal voids of 0.63 (0.14); there was a further reduction attributable to permixon of 0.38 (0.07) (Po0.001). The authors concluded that permixon is associated with a significant improvement in peak flow rate and reduction in nocturia above placebo, and a 5-point reduction in the IPSS in men with BPH.
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